论文部分内容阅读
目的 :探讨抑癌基因环指蛋白180(ring finger protein 180,RNF180)在肝细胞癌及癌旁肝硬化组织中的表达情况及临床意义。方法 :采用免疫组织化学法检测76例肝细胞癌及其对应癌旁肝硬化组织中RNF180的表达情况,并分析肝细胞癌中RNF180的表达与临床病理特征及生存期预后的关系。结果 :RNF180在肝癌组织中的阳性表达率为39.47%(30/76),明显低于癌旁肝硬化组织中的阳性表达率86.84(%66/76),差异有统计学意义(P=0.006);且肝细胞癌组织中RNF180的表达强度明显低于癌旁肝硬化组织(Z=-2.480,P=0.013)。RNF180的阳性表达率在AFP≤200μg/L的肝细胞癌中明显高于AFP>200μg/L的肝细胞癌组织(P=0.031)。RNF180表达阴性组患者的平均生存期为(16.42±6.39)个月,而表达阳性组为(20.40±5.86)个月,差异有统计学意义(P=0.002)。COX多因素分析结果提示,有无门静脉癌栓、肿瘤个数和RNF180表达为影响肝癌患者预后的独立因素。结论 :抑癌基因RNF180在一定程度上参与了肝细胞癌的发生,促进了肝细胞癌的发展进程,RNF180可能成为肝细胞癌诊断、病情判断及预后预测的新的分子标志。
Objective: To investigate the expression and clinical significance of the ring finger protein 180 (RNF180) in hepatocellular carcinoma and adjacent normal liver cirrhosis. Methods: Immunohistochemical method was used to detect the expression of RNF180 in 76 cases of hepatocellular carcinoma and its corresponding paracancerous cirrhotic tissues. The relationship between the expression of RNF180 in hepatocellular carcinoma and clinicopathological features and survival prognosis was analyzed. Results: The positive rate of RNF180 in HCC tissues was 39.47% (30/76), which was significantly lower than that in adjacent noncancerous cirrhosis tissues (86.84%, 66/76) (P = 0.006 ), And the expression level of RNF180 in hepatocellular carcinoma was significantly lower than that in adjacent liver cirrhosis (Z = -2.480, P = 0.013). The positive rate of RNF180 in HCC with AFP≤200μg / L was significantly higher than that in HCC with AFP> 200μg / L (P = 0.031). The mean survival time of patients with negative RNF180 expression was (16.42 ± 6.39) months, while it was (20.40 ± 5.86) months in positive expression group (P = 0.002). COX multivariate analysis showed that there is no portal vein tumor thrombus, the number of tumors and RNF180 expression as an independent factor affecting the prognosis of patients with liver cancer. CONCLUSION: RNF180, a tumor suppressor gene, is involved in the development of hepatocellular carcinoma to a certain extent and promotes the development of hepatocellular carcinoma. RNF180 may be a new molecular marker for the diagnosis, prognosis and prognosis of hepatocellular carcinoma.